import { TimelineData } from "../timelineTypes";

export const depoTimelineData: TimelineData = {
  "2025": {
    firstHalf: [
      {
        date: "January",
        text: "Pfizer agreed to the creation of a multidistrict litigation (MDL) to address the Depo-Provera lawsuits but disagreed with plaintiffs' attorneys on where it should be centralized."
      },
      {
        date: "February",
        text: "A federal judicial panel consolidated 27 cases from eight different districts and transferred them to the Northern District of Florida for pretrial proceedings."
      },
      {
        date: "March",
        text: "The court approved a discovery schedule for five pilot cases, beginning on March 27 and continuing through March 2026."
      },
      {
        date: "April",
        text: "The court set a deadline for generic manufacturers, including Viatris and Greenstone, to formally declare they were not involved in the case."
      },
      {
        date: "May",
        text: "Pfizer produced more than 1 million documents related to Depo-Provera, which were submitted to the court and plaintiffs’ legal teams."
      },
      {
        date: "June",
        text: "Greenstone and Viatris were dismissed from the Depo-Provera litigation, similar to the earlier dismissal of Prasco."
      }
    ],
    secondHalf: [
      {
        date: "July",
        text: "The number of active Depo-Provera lawsuits in federal court reached 550, with over 100 new cases filed in just the past few weeks."
      },
      {
        date: "August",
        text: "Pfizer filed a motion for summary judgment in the Depo-Provera litigation, asking the court to rule in its favor without proceeding to trial."
      },
      {
        date: "September",
        text: "Pfizer claimed the FDA blocked its attempt to add a meningioma warning to the Depo-Provera label after a formal request in 2024."
      },
      {
        date: "October",
        text: "The number of active Depo-Provera lawsuits consolidated in federal court rose to 1,222."
      }
    ]
  },

  "2024": {
    firstHalf: [
      {
        date: "March",
        text: "A French study found that women who received the Depo-Provera shot had a 5.6-times higher risk of developing meningioma."
      },
      {
        date: "April",
        text: "Pfizer acknowledged awareness of the potential long-term health risks associated with prolonged use of progestogens."
      }
    ],
    secondHalf: [
      {
        date: "September",
        text: "A study from the University of Alabama found that Depo-Provera increases the risk of cerebral meningioma."
      },
      {
        date: "October",
        text: "Monique Jones became one of the first women to file a Depo-Provera lawsuit, seeking compensation for injuries related to cerebral meningioma."
      },
      {
        date: "November",
        text: "The lawsuits alleged that Pfizer failed to disclose certain side effects on the drug’s warning label and knew of its potential link to brain tumors."
      },
      {
        date: "December",
        text: "According to the CDC, 42% of Black women and 27% of Hispanic women have used Depo-Provera, highlighting disproportionate exposure risks."
      }
    ]
  }
};
